Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients

Launched by AIN SHAMS UNIVERSITY · May 15, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of two different medications, dapagliflozin and pentoxifylline, on patients with chronic kidney disease (CKD). Dapagliflozin is a newer type of medication that has shown promise in helping to slow down kidney damage, while pentoxifylline is an older drug mainly used for blood circulation issues. The goal of the trial is to see which of these medications is better at protecting the kidneys from further decline.

To participate in this study, individuals need to be between 65 and 74 years old and diagnosed with CKD at stages 2 or 3. However, people with diabetes, recent urinary infections, those taking immune-suppressing medications, or those with cancer cannot join the trial. If eligible, participants will receive one of the medications and will be monitored to assess how well their kidneys are functioning. This trial is currently recruiting participants, and it aims to provide valuable insights into better treatments for CKD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • CKD stage 2 and 3
• Exclusion Criteria:
• • Diabetes mellitus
• • History of recurrent or recent genitourinary infections
• • Immunosuppressive medications
• • Malignancy

Trial Officials